Triptorelin
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Triptorelin: Hypertrichosis (disease)
One-Sentence Summary
Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that is marketed in Canada. The TxGNN model predicts it may be useful for hypertrichosis, but 0 clinical trials and only 1 publication (a case report, which does not show a treatment benefit) were found. The prediction therefore rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 4 of 4) |
| Number of DINs | 4 (marketed: 4) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this drug. Triptorelin is known as a GnRH agonist that suppresses gonadal sex steroids. Hypertrichosis, however, is excessive hair growth that is not tied to a clear hormonal-axis target of triptorelin.
No credible mechanistic link could be established. The only publication retrieved describes hypertrichosis caused by ciclosporin in a transgender woman who was also taking estradiol and triptorelin. In that report hypertrichosis is an adverse effect of a different drug, and it appeared despite androgen suppression. It does not suggest that triptorelin treats the condition.
The high model score is most likely an artifact of the model’s inference and should not be read as clinical support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41822646 | 2026 | Case report | Cureus | Generalised hypertrichosis developed after ciclosporin was started for severe plaque psoriasis in a 25-year-old transgender woman. She was also taking estradiol and triptorelin. Hypertrichosis was an adverse effect of ciclosporin, and the paper gives no evidence that triptorelin treats it. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02240000 | TRELSTAR | Not specified | Not specified |
| 02243856 | TRELSTAR | Not specified | Not specified |
| 02389282 | DECAPEPTYL | Not specified | Not specified |
| 02412322 | TRELSTAR | Not specified | Not specified |
Safety Considerations
- Drug Interactions: 100 interactions were recorded. The most notable is Dolasetron (Major). Moderate interactions include several antidiabetic drugs (e.g. metformin, pioglitazone, glimepiride, chlorpropamide, acarbose, alogliptin, saxagliptin, canagliflozin, dapagliflozin, empagliflozin, dulaglutide, albiglutide). Others are clarithromycin, famotidine, loperamide, palonosetron, and the bowel-preparation agents bisacodyl, picosulfuric acid and polyethylene glycol.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The only evidence for this prediction is the model score. The single publication reports hypertrichosis as a side effect of another drug and gives no sign that triptorelin helps, and no clinical trials exist. With no study of triptorelin in this disease, the evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data to assess whether any plausible link to hypertrichosis exists
- Package insert warnings and contraindications from Health Canada
- Any direct clinical or preclinical study of triptorelin in hypertrichosis, before further consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.